Abstract-The versican (PG-M) gene encodes a chondroitin sulfate proteoglycan that is nonpermissive for cell migration and appears in association with slow cell proliferation and cytodifferentiation. Using the techniques of in situ hybridization and immunocytochemistry on sectioned mouse embryos, we found that the mRNA and protein for versican show similar distributions and are expressed in a dynamic pattern during development of the heart. Versican exhibits generalized expression in the tubular heart but becomes rapidly downregulated in the atrium and exhibits higher transcript levels on the right side of the ventricular chamber than the left, before the onset of ventricular septation. Versican is expressed strongly in the trabeculated ventricular myocardium, whereas the compact proliferative zone has lower transcript abundance. It is expressed in the outer layers and on the crest of the ventricular septum and is prominent on the mesenchymal cap of the primary atrial septum. Versican is particularly strongly expressed in the endocardial cushions of the atrioventricular and outflow tract regions and in the atrioventricular, semilunar, and venous valves. This study raises the possibility that versican may be involved in specification of the ventricular chambers, in growth and fusion of the atrial and ventricular septa, and in the transformation from epithelium to mesenchyme that characterizes development of the endocardial cushions. Versican may be a key participant in cardiogenesis, responding to the many diffusible signals that mediate interactions between the developing endocardium and myocardium. (Circ Res. 1998;83:523-532.)
R ecent years have seen a dramatic increase in the number of genes known to be expressed in the developing heart. Moreover, the advent of gene-targeting technology [1] [2] [3] has provided a wide range of mutant mice that develop heart defects, thereby identifying model systems with which to probe the origins of human congenital cardiac disease. Gene targeting has revealed key roles for MEF2c and dHAND in chamber specification 4, 5 and has pointed to the importance of neuregulin, N-myc, neurofibromatosis-1 (NF-1), and retinoid X receptor-␣ in the development of septa and endocardial cushions. 6 -11 These advances in the identification of some of the key genes of cardiac development open the way toward understanding the cascades of gene expression that underlie events such as chamber specification and the formation of valves and septa. It is striking, however, that although a number of transcription factors and signaling molecules have been shown to play a functional role in heart development, much less is known about the genes downstream from these regulatory molecules, which are likely to mediate the cellular interactions that constitute heart development. The present study describes the expression of one such gene, versican.
Versican (or PG-M) is a chondroitin sulfate proteoglycan expressed in the pathways of neural crest cell migration and in prechondrogenic areas of the developing chick and mouse. 12, 13 This molecule has been proposed to be nonpermissive for cell movements and is expressed in barrier tissues for neural crest migration and neurite outgrowth. [12] [13] [14] Versican is also associated with regions of epithelium to mesenchyme transformation within the developing mouse embryo (D.J. Henderson, M. Kolatsi-Joannou, and A.J. Copp, unpublished data, 1998). To study the role of versican in cardiac development, we examined the expression of the mRNA and protein by in situ hybridization and immunocytochemistry, respectively, in developing mouse hearts from embryonic day (E) 8.5, before cardiac looping has begun, until E14.5, when septation is complete and the cardiac valves have formed. Versican gene expression occurs at high levels in specific regions of the developing heart throughout this period of embryogenesis. Specifically, versican is expressed in a chamber-specific manner, with downregulation in the atrium as the heart loops. It is expressed at much higher levels in the trabeculations of the right than the left ventricle, before formation of the ventricular septum is apparent, and is found in the crest of the developing atrial and ventricular septa and throughout the development of the endocardial cushions and valves. Our findings suggest that versican may play multiple roles in cardiac development, including regulation of chamber specification, growth and fusion of septa, and modeling of the endocardial cushions.
Materials and Methods

Mouse Strains and Embryos
Randomly bred CD1 mice were used throughout the study. Females were placed with males overnight and checked for copulation plugs the following morning. Noon on the day of finding a plug was designated 0.5 days of gestation (E0.5). Pregnant females were killed by cervical dislocation, and the embryos were placed in DMEM (GIBCO) containing 10% FCS. The yolk sac and amnion were opened, and the umbilical cord was cut. For in situ hybridization, embryos were washed in PBS and then fixed in 4% paraformaldehyde in PBS by immersion overnight at 4°C, followed by dehydration and embedding in paraffin wax. For immunocytochemistry, embryos were washed in PBS and then immersed in St Marie's fixative (1% acetic acid and 95% ethanol) overnight at room temperature. The embryos were washed twice in 100% ethanol and processed for embedding in paraffin wax.
Radioactive In Situ Hybridization on Paraffin Wax-Embedded Sections
Oligonucleotide primers were designed in order to amplify 2 regions of the sequence encoding the versican core protein as described by Ito et al. 15 The regions amplified corresponded to base pairs 1469 to 2029 and 6919 to 7357 of the published sequence. These regions correspond to the ␣ and ␤ domains of the core protein, respectively, and show Ͻ15% homology at the amino acid level to any known genes, including the other chondroitin sulfate proteoglycans (aggrecan, neurocan, and brevican). This makes cross hybridization with other chondroitin sulfate proteoglycans very unlikely. The corresponding DNA fragments were amplified by polymerase chain reaction, cloned into a plasmid vector, and sequenced, as described previously. 13 The plasmids were used to produce 35 S-labeled riboprobes, and in situ hybridization was carried out according to a standard protocol, 16 with modification as follows: Briefly, 8-m paraffin sections were dewaxed and rehydrated, treated with 20 g/mL proteinase K for 8 minutes, washed in PBS, dipped in 0.5% acetic anhydride, dehydrated, and air-dried. Labeled probe was applied to the sections at a final concentration of 5ϫ10 4 cpm/L at 55°C overnight in a humid environment. The sections were washed at high stringency to 0.1ϫ SSC at 50°C, dipped in Ilford K5 emulsion, and exposed in the dark for up to a week at 4°C. After development, the sections were counterstained with toluidine blue, mounted, and photographed using a Zeiss Axiophot microscope. Probes to both the ␣ and ␤ domains showed identical expression patterns in initial experiments, so the probe for the ␤ domain alone was used in all further experiments. In no case did sense controls show hybridization above background.
Immunocytochemistry for Versican on Paraffin Wax-Embedded Sections
A polyclonal antiserum to the ␤ domain of mouse versican was obtained as a gift from Dr T. Shinomura (Nagakute, Japan). The antibody is an affinity-purified preparation of antiserum, raised from a fusion protein of the ␤ domain of versican expressed in Escherichia coli (T. Shinomura and K. Kimata, unpublished data, 1998). Briefly, 8-m sections were dewaxed, rehydrated, and treated with 3% hydrogen peroxide in deionized water for 5 minutes to block endogenous peroxidase. The sections were subsequently blocked for 15 minutes with serum-free block (Dako). The versican antibody was diluted 1:20 in 2% rat serum in Tris-buffered saline and incubated with the sections for 2 to 3 hours at room temperature. The sections were washed in Tris-buffered saline and then overlaid with a diluted (1:600 with 2% rat serum in Tris-buffered saline) biotinylated goat anti-rabbit secondary antibody (Dako) for 1 hour at room temperature. This was followed by incubation with horseradish peroxidaselinked avidin (Dako) to amplify the signal. Positive signal was detected by incubation with metal-enhanced diaminobenzidine tetrahydrochloride (Sigma Chemical Co) as a substrate for horseradish peroxidase. Rabbit serum was used in place of the primary antibody as a negative control. In no case was signal above background seen in these sections. The sections were counterstained with toluidine blue, dehydrated, mounted, and photographed using a Zeiss Axiophot microscope.
Results
To investigate the expression pattern of versican mRNA in the developing mouse heart, we hybridized 35 S-labeled riboprobes specific for the versican core protein to serial sections of mouse embryos harvested at intervals between E8.5 and E14.5. This was complemented with immunocytochemistry for versican protein.
Versican mRNA Expression is Chamber Specific
Versican transcripts can be seen in the heart of E8.5 embryos with 5 or 6 somites ( Figure 1A and 1B). At this stage, the heart consists of a double-layered tube, in which myocardium surrounds the inner endocardium, with extracellular cardiac jelly in between. Versican mRNA is present solely in the myocardium (small arrowheads in Figure 1B ) and is absent from the endocardium (arrows in Figure 1B) . Analysis of serial sections shows that versican transcripts are found throughout the length of the heart tube at this stage (data not shown). Versican is also expressed in the splanchnic lining of the dorsal mesocardium, where the heart tube is attached to the body wall (large arrowheads in Figure 1B ). As the heart tube begins to loop at E9.0 (11 to 13 somites), versican mRNA continues to be expressed in the myocardium of the outflow tract and ventricle, whereas it is rapidly downregulated in the presumptive atrial region ( Figure 1C ). This regional difference in versican expression occurs before endocardial cushions have formed in the atrioventricular canal and before any morphological differences can be discerned between atrial and ventricular chambers. Versican transcripts are not seen in the atrial myocardium at any subsequent stage of development.
Expression differences between the presumptive right and left ventricles can be seen at E9.0 (arrowheads indicate more intense expression in the right ventricle in Figure 1C ). This is before any evidence of trabecular formation and well before the onset of ventricular septation. At E10.0 to E10.5, the site at which the ventricular septum will form can be distinguished (arrows in Figure 1D and 1E). Although versican mRNA continues to be expressed in both right and left sides of the ventricle, transcripts are more abundant in the presumptive right ventricle and outflow tract than in the left ventricle ( Figure 1D to 1F). This difference in expression between the right and left sides of the heart becomes even more obvious at E11.5, when a sharp boundary of expression can be seen between the trabeculations of the presumptive right and left ventricles ( Figure 1H ). This boundary coincides precisely with the site of the developing ventricular septum, which, in some preparations, appears to be "bisected" by the boundary between high-and low-expression domains of versican. By E12.5, versican expression is declining in both ventricles (Figure 2A and 2B), and at E13.5, transcript levels are almost indistinguishable between the 2 ventricles ( Figure  2D ). Versican mRNA expression is completely absent from the ventricle by birth, remaining only in the valves ( Figure  2F ). Thus, asymmetry of versican expression precedes the morphological division of the common ventricle into right and left chambers.
Versican Is Expressed in the Trabeculations of the Developing Myocardium
Between E9.5 and E11.5, the ventricle develops from a simple thin-walled sac (closely resembling the atrial chamber) into a complex structure with trabeculations and a myocardial wall several cell layers thick. Trabeculations are Figure 1 . Versican mRNA expression during septation of the heart between E8.5 and E11.5. Bright-field (A) and dark-field (B to I) micrographs of transverse sections through mouse embryonic hearts after hybridization for versican mRNA. A and B, Versican transcripts are present in the myocardium (m, small arrowheads) but not the endocardium (e, arrows) of the heart tube at E8.5 (5-to 6-somite stage). Expression is also seen in the inner lining of the dorsal mesocardium (large arrowheads), which joins the heart to the body wall. C, Versican is downregulated in the presumptive common atrium (a) of the looping heart at E9.0. The presumptive right ventricle (rv) now expresses versican at a higher level (arrowheads) than the developing left ventricle (lv), preceding morphological evidence of chamber septation. D, With differentiation of the myocardium at E10.0, versican is expressed more intensely in the trabeculations of the presumptive rv (small arrowheads) compared with the lv. Arrow indicates site of future formation of the ventricular septum. Versican transcripts are also seen in the roof of the atrium where an epithelium to mesenchyme transformation takes place and the atrial septum first appears (large arrowheads). E, At E10.5, the trabeculations in the ventricle are more pronounced, the site of the ventricular septum can be distinguished (arrow), and the atrioventricular endocardial cushion tissue (c) expresses versican mRNA strongly. The atrial septum is beginning to grow down from the roof of the atrium and expresses versican throughout its length (large arrowheads). F, Versican mRNA is expressed in the outflow tract (ot) cushions (arrowheads) as they first develop at E10.5. G, Strong expression of versican mRNA is seen in the ot cushions at E11.5 (arrowheads). H, At E11.5, versican expression is much more intense in the rv than lv. The boundary of expression can be seen to bisect the ventricular wall at the junction of the prospective rv and lv (arrows). I, By E11.5, the atrial septum is approaching the atrioventricular endocardial cushions with which it will eventually fuse. At this stage, versican is downregulated in the main body of the septum (arrow) but is strongly expressed in the leading edge (small arrowhead). In addition, the developing valves guarding the entry of the superior caval vein into the right atrium (ra) express versican mRNA (large arrowhead). la indicates left atrium. Versican mRNA continues to be expressed in the developing valves of the heart from E12.5 through to the neonatal period. Shown are bright-field (C and E) and dark-field (A, B, D, and F) micrographs of transverse sections through mouse hearts after hybridization for versican mRNA. A, Versican mRNA continues to be expressed strongly in the atrioventricular endocardial cushions (c) after fusion of the ventricular septum at E12.5. Versican is also expressed in the leaflets of the venous valves (arrowheads) guarding the entry of the superior caval vein (scv) into the right atrium (ra). B, Section is through the same heart as in panel A but at a more cranial level. Although the ventricular septum (s) has fused with the atrioventricular cushions at E12.5, it has not yet made contact with the outflow tract (ot) septum. At this stage, the core of the ventricular septum has downregulated versican expression, whereas the crest (arrowheads) and outer layers of the septum are still positive for versican mRNA. C and D, At E13.5, versican mRNA expression is declining throughout the ventricles, and the difference in expression between the ventricles is no longer evident. Note strong expression first visible at E10.0 (23 to 25 somites), at which time the myocardial wall is still thin, with only 1 or 2 cell layers. At this stage, versican is expressed at a high level in the developing trabeculations but at a much lower level in the wall of the myocardium ( Figure 3A and 3B) . As trabeculation proceeds, expression of versican reaches a peak of intensity, with transcripts abundant in both trabeculations and myocardial wall ( Figure 3C and 3D) . At E12.5 to E13.5, the ventricular wall differentiates to form a compact outer layer and an inner spongy layer. Versican expression becomes downregulated in both the compact and spongy layers of the myocardial wall but is maintained in the trabeculated myocardium ( Figure 3E and 3F) . Later, as the trabeculations differentiate to form the papillary muscles and the tendinous cords that connect the muscles to the atrioventricular septum, the expression of versican becomes less intense, so that by the time of birth, versican is no longer expressed in the ventricle (data not shown).
Versican Is Expressed in the Septa Dividing the Atria, Ventricles, and Outflow Tract
The common atrium of the mouse heart begins to divide at E9.5 as a result of the formation, modification, and eventual fusion of the primary and secondary atrial septa. During this process, the primary septum grows out from the roof of the atrium, and its mesenchymal cap fuses with the atrioventricular endocardial cushions. Perforations appear in the septum, allowing flow of blood between the right and left atria. In embryos harvested at E10.0, versican mRNA can be detected in the region of the atrial wall where a thickening marks the site of formation of the primary septum ( Figure 1D ). This septum begins to grow out at E10.5 and initially expresses versican throughout its length ( Figure 1E ). By E11.5, the septum has grown down from the roof of the atrium, forming a thin muscular structure with a mesenchymal cap. 17 Versican mRNA can clearly be detected in the crest of the septum (small arrowhead in Figure 1I ), whereas the remainder of the septum is now negative for versican mRNA (arrow in Figure  1I ). By E12.5, the mesenchymal cap of the primary septum has fused with the atrioventricular cushions. Versican appears to be completely downregulated in the primary septum once fusion with the atrioventricular cushion tissue has taken place ( Figure 2A [arrow] , 2C, and 2D [arrows]). At E12.5 to E13.5 of development, the atrioventricular cushion tissue expresses versican intensely, and there is a clear boundary of expression between the negative septum and the positive cushion tissue ( Figure 2C and 2D) . The secondary atrial septum does not appear to express versican mRNA at any stage of its development (data not shown).
The ventricular septum first appears at E10.0 in the floor of the versican-positive ventricular chamber. At this stage, versican expression in the rudimentary septum is indistinguishable from that in the rest of the trabeculations (arrow in Figure 1D ). At E11.5, the growing septum exhibits heterogeneity of versican mRNA expression, with the right side expressing at a higher level than the left side (data not shown), reflecting the differences in expression of versican mRNA between the right and left ventricles ( Figure 1H ). By E12.5, the septum has fused with the atrioventricular cushions (Figure 2A) but has not yet fused with the outflow tract septum ( Figure 2B ). At this stage, the core of the septum expresses versican only at a low level, in a manner similar to that in the compact zone of the ventricular wall, whereas the outer layers of the septum continue to express versican more intensely, with the leading edge exhibiting particularly strong expression (arrowheads in Figure 2B ). At E13.5, after the septum has fused with the atrioventricular cushions and with the septum of the outflow tract, the former crest of the ventricular septum retains high expression of versican transcripts, whereas the core of the septum continues to express versican at a lower level than the outer layers ( Figure 2D ).
Intense Expression of Versican in the Endocardial Cushions and Developing Valves
Endocardial cushions first appear in the looping heart tube at about E9.5. They consist of swellings within the atrioventricular canal and outflow tract in which endocardial cells transform from an epithelial to mesenchymal morphology, and they migrate throughout the cardiac jelly toward the myocardium. Versican transcripts can be detected at E10.0 in the early atrioventricular endocardial cushions ( Figure 1D ). This expression is detected as the cells deepithelialize and migrate into the cardiac jelly. No versican mRNA is detected in the presumptive cushions before the transformation process. By E10.5, versican is strongly expressed in the endocardial cushions of the atrioventricular canal ( Figure 1E ) and in the newly developing truncal ridges of the outflow tract ( Figure 1F ). As the loose early endocardial cushion develops into the cell-dense structure characteristic of the more mature valvular tissue, versican mRNA expression increases in both the atrioventricular and outflow tract cushions ( Figure 1G and 1I). The atrioventricular ( Figure 2D ) and semilunar (large arrowheads in Figure 2E ) valves remain strongly positive for versican mRNA throughout the remainder of fetal development. However, in the more distal region of the outflow tract, mRNA transcript expression is downregulated throughout the walls of the aorta and the pulmonary trunk after their separation ( Figure 2E) . Interestingly, the valves guarding the entry of the superior caval vein are also versican-positive throughout their development, even though these structures do not arise from endocardial cushions (large arrowheads in Figures 1I, 2A, and 2D ). Versican mRNA continues to be expressed in the mitral and tricuspid valves of the neonatal mouse heart (Figure 2F ), suggesting that versican may be involved in the continued remodeling of the valve leaflets after birth.
in the tricuspid and mitral valve leaflets (small arrowheads). The boundary between the atrial septum and the strongly expressing endocardial cushion can clearly be seen (arrows). The valves of the scv continue to express versican mRNA (large arrowhead). E, At E13.5, versican is expressed in the distal ot cushions (appearing as dark brown staining, small arrowheads) and in the developing semilunar valves (large arrowheads) but is completely absent from the aortopulmonary septum (arrow). F, Versican continues to be expressed in the leaflets of the atrioventricular valves of the neonatal heart (arrowheads). lap indicates left atrial appendage; la, left atrium; lv, left ventricle; and rv, right ventricle. Barϭ200 m. 
Versican Protein Mimics the Pattern of the mRNA Expression Throughout Heart Development
Localization of versican protein during heart development in the mouse embryo reveals a pattern broadly similar to versican mRNA expression. At E8.5 to E9.5, protein is found surrounding both the endocardial and myocardial cells in the presumptive atrial and ventricular regions ( Figure 4A ). This suggests that the restriction of versican protein to the ventricle occurs slightly later in development than the restriction of the mRNA. However, by E10.5 versican is downregulated in the atrium (Figure 4B and 4C) but is found surrounding the endocardium of the common ventricle ( Figure 4B ). Versican is still found surrounding the endocardial cells until E11.5 but is also found in the myocardium at this stage of development ( Figure 4C ). Versican expression in the developing ventricle is downregulated by E12.5 ( Figure 4F and 4G) .
Versican is also abundant in the developing atrioventricular and outflow tract cushions and in the atrial septum as it begins to form, mirroring the mRNA pattern ( Figure 4B to 4G). Moreover, at E11.5, versican staining is noticeably more intense in the right ventricle than in the left ventricle ( Figure  4C ), as was also seen in the mRNA study ( Figure 1H ). Although protein levels are declining in the ventricular myocardium at E12.5, expression can still be seen in the developing valves ( Figure 4F and 4G [arrows] ). Interestingly, staining can be seen throughout the development of the venous valves, supporting a role for versican in the development of these structures (arrowheads in Figure 4F and 4G).
Discussion
We have studied the cardiac expression, at both mRNA and protein levels, of the chondroitin sulfate proteoglycan versican (PG-M) from the earliest stages of mouse heart tube formation until the neonatal period. We find it to be associated with all aspects of valve and septum formation. In addition, versican is expressed in the myocardium in a chamber-specific manner before any morphological indications of septation have occurred. This myocardial expression is restricted to the developing trabeculations, showing rapid downregulation in the myocardial wall. These differences may reflect a role in specification of the ventricles and/or functional differences between the 2 ventricles.
Versican May Be Involved in Chamber Specification
Versican mRNA is expressed initially in the myocardium throughout the heart tube, but this generalized expression is quickly downregulated in the presumptive atrium as the heart loops at E9.0 (11 to 13 somites). At the same time, versican becomes differentially expressed between the presumptive right and left ventricles, and by E10.5, it is clearly expressed in a right ventricle-specific manner. Versican protein is expressed in a similar pattern, with the right ventricle showing more abundant staining than the left. This right ventriclespecific expression pattern mirrors the expression of the basic helix-loop-helix gene dHAND, 5 raising the possibility that versican may be regulated by dHAND. MEF2c, a known regulator of skeletal, smooth, and cardiac myogenesis, 18, 19 is expressed throughout the myocardium of the developing heart. It was proposed recently that the MEF2c protein might promote right ventricle-specific expression by binding to a regulatory region within several genes, including myosin light chain-2 and desmin. 20, 21 This raises the possibility that MEF2c is upstream from dHAND in a cascade to specify the right ventricle. 4 It is possible, therefore, that the versican gene promoter might also contain an MEF2c binding site or that MEF2c might regulate versican via dHAND. Although gene knockouts exist for dHAND and MEF2c, both types of null mutant embryos fail to develop a right ventricle, 4,5 precluding a study to determine whether the right ventricle-specific expression of versican is dependent on expression of these transcription factors.
Apart from the HAND genes, versican is the only characterized gene to be expressed in a ventricular chamberspecific manner before chamber septation, raising the possibility that it may have a functional role in the specification of the chambers. The ventricular septum develops precisely at the junction between the domains of high and low intensity of versican expression. Thus, it is possible that the boundary of versican expression may be involved in specifying the site at which the ventricular septum forms. Versican expression has been associated with changes in cell fate and the proliferative rate 12, 22 (D.J. Henderson, M. Kolatsi-Joannou, and A.J. Copp, unpublished data, 1998), both of which might play a part in chamber specification. A random transgene insertion has located another gene, named hdf, which also has right ventricle-specific expression before chamber septation. 23 Mice homozygous for this insertional mutation die at E10.5 of gestation, with abnormalities of the endocardial cushions and the ventricular trabeculations, both of which exhibit strong versican expression. Moreover, the hdf integration site is mapped close to the versican locus on mouse chromosome 13, [23] [24] [25] raising the possibility that the hdf insertion is within the versican gene. Indeed, recent unpublished mapping data support versican as a strong candidate for the gene mutated by the hdf mutation (C. Mjaatvedt, written communication, 1998). A number of other structural genes, including SM22, have also been shown to be differentially expressed between the ventricles. These differences appear after chamber septation, however, and seem likely to reflect differences in maturation rate of the myocardium in the 2 chambers rather than a role in chamber specification.
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Versican May Be Involved in Signaling Between the Endocardium and Myocardium
Versican transcripts are seen initially throughout the myocardium, but expression becomes upregulated in the developing ventricular trabeculations. This high level of expression is maintained until the trabeculations form the papillary muscles and tendinous cords that contribute to the mature cardiac skeleton. Versican protein is most abundant surrounding the endocardial cells, with lower levels surrounding the myocardial cells in the preseptation heart. Versican is an extracellular matrix protein that is secreted from the cell and is thought to play a role in cell-cell or cell-substratum adhesion. It appears therefore that versican is synthesized in the myocardium and is secreted to surround the endocardium. This suggests that versican may have a role in the interaction between myocar- 
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Gene targeting has revealed the importance of these molecules for trabeculation and septation of the ventricles. 6, 27, 28 If the neuregulin or angiopoietin-1 signaling pathways are disrupted, the ventricle remains untrabeculated, and the ventricular septum does not form, supporting a role for signaling between the endocardium and myocardium in the development of trabeculae. Versican is expressed at sites of cell-cell interaction throughout the developing mouse embryo (D.J. Henderson, M. Kolatsi-Joannou, and A.J. Copp, unpublished data, 1998), and this supports a general role for versican in mediating interactions between different cell types during development.
Versican Is Regulated According to the Proliferative and Differentiated State of Myocardial Cells
As the myocardial wall develops, versican becomes downregulated in the outer compact layer but is maintained in the spongy inner layer. Similarly, versican is abundant in the outer layer and crest of the ventricular septum but is downregulated in the inner core. Proliferative differences are known to exist in the ventricular myocardium, with a rapid rate of proliferation in the compact zone of the myocardial wall and the core of the ventricular septum and a slower proliferative rate in the trabeculations and outer layers of the ventricular septum. 29, 30 The N-myc transcription factor is associated with cell proliferation 7 ; consistent with this role, N-myc is expressed in the compact zone of the ventricular myocardium and in the core of the ventricular septum but not in the more slowly dividing trabeculations and outer layers of the septum. 31 The expression of N-myc is therefore reciprocal to versican, reinforcing the idea that versican is expressed in differentiating rather than rapidly proliferating cells. A number of mouse mutants have defects in trabeculation and the formation of the ventricular septum. These include N-myc and NF-1, both of which are thought to be involved in the control of cell proliferation.
7,9 NF-1 is thought to negatively regulate proliferation, whereas N-myc stimulates proliferation, suggesting that these processes are tightly coupled in the myocardium. It will be interesting to determine whether downregulation of versican expression is necessary for differentiation of the myocardium and/or growth of the core of the ventricular septum. Versican expression has also been shown to be related to the proliferative/differentiated state in the dermis, where versican is abundant at low cell densities but is downregulated when cell density is high or when cells undergo terminal differentiation. 22 The authors of that study 22 suggest that versican may serve to modulate cell proliferation and it may be that, in the developing heart, versican may also play a regulatory role, perhaps directing the switch from rapid proliferation to differentiation of the myocardium. Cardiomyocytes undergo terminal differentiation during the neonatal period, when versican is completely switched off in the ventricle. This suggests that versican may need to be downregulated before terminal differentiation can take place.
A Role for Versican in Epithelium to Mesenchyme Transformation
Before E9.5 in the mouse, the endocardial cushions constitute an acellular accumulation of extracellular matrix ("cardiac jelly") enclosed by endocardium and myocardium. From E9.5, endocardial cells overlying these sites undergo an epithelium to mesenchyme transformation, under the influence of the myocardium, and migrate into the cardiac jelly to form the loose mesenchymal structure of the cushion tissue. [32] [33] [34] The endocardial cushions then act as primitive valves within the looping heart. We have shown that versican is expressed in cushion tissue as cells delaminate from the endocardium and migrate into the cardiac jelly and that it continues to be expressed in the developing valves into the neonatal period. Endocardial cells do not express versican mRNA transcripts, although the protein is found surrounding these cells up to around E11.5.
Versican is also expressed throughout the development of the primary atrial septum. It is found initially in the roof of the atrium as the septum is forming, but as the septum grows toward the endocardial cushions, it is expressed solely in the mesenchymal crest. Neural cell adhesion molecule, which is expressed by the endothelial cells of the developing septum, becomes polysialylated coincident with this cellular change, possibly mediating a reduction in cell-cell adhesion and thereby facilitating cell migration. 35 The expression of versican may well be involved in this same cellular process, providing an antiadhesive influence to facilitate cell migration as the atrial septum grows toward the endocardial cushions. Interestingly, versican is also found in the developing venous valves, which are not known to arise from endocardial cushion tissue or to involve an epithelial to mesenchyme transformation. It is possible that the venous valves do in fact develop by a process of epithelialmesenchymal transformation or that versican has a role in the sculpting of the valves after they have formed.
Versican is well known for its antiadhesive properties, 36, 37 and its expression at sites of epithelial-mesenchymal transformation may mediate the detachment and migration of mesenchymal cells rather than play a role in the transformation process itself. Versican binds to hyaluronan 38 and colocalizes with tenascin at numerous sites during development and in the adult. 39 Hyaluronan and tenascin are expressed in the developing endocardial cushions, 40, 41 and it is possible that versican interacts with these molecules to mediate downstream events. Versican is also expressed at sites of epithelialseptum is negative for versican staining (arrow). E, Versican is expressed in the developing truncal ridges (arrowheads) of the outflow tract (ot) at E11.5. F, At E12.5, versican is downregulated in the developing ventricular myocardium but is found surrounding the endocardial cells on the crest of the ventricular septum (large arrowheads). The venous valves (small arrowhead) continue to express versican at this stage of development. G, Versican is still found in the developing atrioventricular valves (arrows) and venous valves (arrowhead) at E13.5. la indicates left atrium; ra, right atrium. Barϭ50 m (A and D), 100 m (B, C, and E), and 200 m (F and G).
mesenchymal transformation outside the heart in developing chick and mouse embryos 12 (D.J. Henderson, M. KolatsiJoannou, and A.J. Copp, unpublished data, 1998), providing support for a generalized role of versican in these cellular transformations.
